Analyst Ratings For Enanta Pharmaceuticals (NASDAQ:ENTA)
Today, Royal Bank of Canada raised its price target on Enanta Pharmaceuticals (NASDAQ:ENTA) to per share.
Some recent analyst ratings include
- 2/8/2018-JPMorgan Chase & Co. was Downgraded by analysts at JPMorgan Chase & Co. from a “Overweight ” rating to a ” Neutral” rating.
Recent Insider Trading Activity For Enanta Pharmaceuticals (NASDAQ:ENTA)
Enanta Pharmaceuticals (NASDAQ:ENTA) has insider ownership of 10.56% and institutional ownership of 67.86%.
- On 1/4/2017 Yat Sun Or, Insider, sold 13,921 with an average share price of $35.09 per share and the total transaction amounting to $488,487.89.
- On 11/29/2016 Yat Sun Or, Insider, sold 13,921 with an average share price of $31.44 per share and the total transaction amounting to $437,676.24.
- On 5/11/2016 Nathaniel S Gardiner, VP, bought 500 with an average share price of $24.45 per share and the total transaction amounting to $12,225.00.
- On 2/12/2016 Terry Vance, Director, bought 2,000 with an average share price of $27.04 per share and the total transaction amounting to $54,080.00.
- On 11/24/2015 Paul J. Mellett, CFO, sold 6,000 with an average share price of $30.15 per share and the total transaction amounting to $180,900.00.
- On 10/15/2015 Paul J Mellett, CFO, sold 7,500 with an average share price of $40.10 per share and the total transaction amounting to $300,750.00.
- On 9/8/2015 Paul J. Mellett, CFO, sold 7,500 with an average share price of $39.55 per share and the total transaction amounting to $296,625.00.
Recent Trading Activity for Enanta Pharmaceuticals (NASDAQ:ENTA)
Shares of Enanta Pharmaceuticals closed the previous trading session at 79.24 down -9.82 11.03% with 87.01000213623047 shares trading hands.